SNAI2: A Promising Protein for Drug Targets and Biomarkers (G6591)

Target Name: SNAI2

NCBI ID: G6591

SNAI2

SNAI2: A Promising Protein for Drug Targets and Biomarkers

SNAI2 (slugH1) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and blood vessels. It is a key regulator of cell signaling pathways, and its dysfunction has been implicated in a number of neurological and cardiovascular diseases.

One of the most promising aspects of SNAI2 is its potential as a drug target. Researchers have identified several unique features of SNAI2 that make it an attractive target for drug development, including its high stability, its expression in a variety of tissues, and its involvement in multiple signaling pathways.

SNAI2's stability is one of its most promising characteristics. Unlike many proteins that are quickly broken down by the body, SNAI2 is highly stable and can remain active for extended periods of time. This stability is important for SNAI2's function as a regulator of cell signaling pathways because it allows it to participate in these processes for longer periods of time.

Another key feature of SNAI2 is its expression in a variety of tissues. While SNAI2 is primarily expressed in the brain and heart, it is also expressed in other tissues, including the blood vessels, liver, and muscle. This makes it an attractive target for drugs that are effective in multiple tissues.

Finally, SNAI2's involvement in multiple signaling pathways makes it an attractive target for drug development. SNAI2 has been shown to be involved in a number of signaling pathways, including the TGF-β pathway, the Wnt pathway, and the Hedgehog pathway. These signaling pathways are involved in a variety of processes in the body, including cell growth, differentiation, and survival. Therefore, drugs that can modulate these pathways may be effective in treating a wide range of diseases.

In addition to its potential as a drug target, SNAI2 is also a potential biomarker. Its stability and expression in a variety of tissues make it an attractive candidate for use as a biomarker for a variety of diseases, including neurological and cardiovascular diseases.

Overall, SNAI2 is a promising protein that has the potential to be a drug target or biomarker. Its stability, its expression in a variety of tissues, and its involvement in multiple signaling pathways make it an attractive candidate for drug development. Further research is needed to fully understand the functions of SNAI2 and its potential as a drug or biomarker.

Protein Name: Snail Family Transcriptional Repressor 2

Functions: Transcriptional repressor that modulates both activator-dependent and basal transcription. Involved in the generation and migration of neural crest cells. Plays a role in mediating RAF1-induced transcriptional repression of the TJ protein, occludin (OCLN) and subsequent oncogenic transformation of epithelial cells (By similarity). Represses BRCA2 expression by binding to its E2-box-containing silencer and recruiting CTBP1 and HDAC1 in breast cells. In epidermal keratinocytes, binds to the E-box in ITGA3 promoter and represses its transcription. Involved in the regulation of ITGB1 and ITGB4 expression and cell adhesion and proliferation in epidermal keratinocytes. Binds to E-box2 domain of BSG and activates its expression during TGFB1-induced epithelial-mesenchymal transition (EMT) in hepatocytes. Represses E-Cadherin/CDH1 transcription via E-box elements. Involved in osteoblast maturation. Binds to RUNX2 and SOC9 promoters and may act as a positive and negative transcription regulator, respectively, in osteoblasts. Binds to CXCL12 promoter via E-box regions in mesenchymal stem cells and osteoblasts. Plays an essential role in TWIST1-induced EMT and its ability to promote invasion and metastasis

The "SNAI2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNAI2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets